Two months after Seattle Post-Intelligencer's parent company Hearst Corp announced that the daily newspaper, marred by losses, will be shut if it could not fetch a buyer, the late Monday and early Tuesday print edition of the paper will be the last ones.
With the closing down of P-I, Hearst will focus entirely on its digital operations - operating an online only news enterprise in Seattle.
About the P-I shut down move, the Hearst group president, Steven Swartz, said: "This is an effort by Hearst to build a local digital media business in Seattle. At its core is a great website that today gets traffic far out of proportion with its circulation levels."
In an attempt to enhance its Seattlepi. com website operations, P-I intends undertaking measures like - launching new blogs from well-known area residents; initiating 150 blogs written by readers; and setting up a local digital advertising agency.
According to Nielson data, the P-I site - which has shifted from the Times-operated domain to its own web domain - already attracts nearly 1.8 million unique monthly visitors, though in-house studies put the figures at almost 4 million. In comparison, the print edition of the newspaper had an average 117,600 weekday circulation.
So far as the 170-odd P-I staffers are concerned, some have lost their jobs, while others will continue with the new P-I website.
Popular content
Today's:
All time:
Last viewed:
- U.S. Stocks Fall Reports Falling Earnings and Deteriorating Performance
- Air Berlin Reduces Boeing 787 Aircraft Orders to 15
- Lloyds may show a profit of 1 billion pounds this year
- Scribner seals deal for publishing Laura Bush’s memoirs
- Chris Christie files papers to run for New Jersey governor
- Defective Genes Pointed Out as Cause of Stuttering, Shows Study
- Guidance and Counseling for Caretakers of Alzheimer’s Patients
- Orbitz Worldwide inks distribution pact with Millennium and Copthorne Hotels
- Report Calls for National Effort to Deal with Dementia "Before it's Too Late"
- Safety Plans to Curb Abuse of Painkillers Presented by Drug Manufacturers



























